Although, type 2 responses by ILC2s have classically been associated with the promotion of TME; in a study carried out in a mouse model of lymphoma, it was reported that if ILCs were activated by stimuli such as IL-33, they could develop an immune protection resulting in decreased tumour growth [359] and in an indirect support of anti-tumour immunity by enhancing both, MHC-I expression on DCs as well as T cell cytotoxicity, as described in primary and metastatic murine lung [172] (Table 1). The gene discussed is IL33; the disease is neoplasm.